‟We propose the use of holographic microscopy for assessing drug induced cell growth alterations. Holographic microscopy is a high-resolution imaging technique that enables real-time detection and quantification of both single as well as whole populations of cells, without the need for prior cell extraction, staining or exposing cells to harmful light sources. Compared to conventional approaches, PHI’s holographic microscope allows non-destructive analysis of cellular characteristics”, says article author Maria Falck Miniotis, Malmö University.
‟Conventional methods require removal of a portion of the cancer cells from their culture environment or wasting precious patient samples by the use of destructive staining. This invasive multi-step approach is sample-wasting and time-consuming and calls for new and improved technology for cancer cell analysis of response to targeted treatment”, continuous Maria Falck Miniotis.
‟The article authors at Malmö University are one of our initial customers in our growing list of customers. We congratulate the University team on their article acceptance for scientific publication. We expect that their pioneering work will soon be followed by others who are using our technology”, concludes Peter Egelberg, CEO PHI.
The article by Maria Falck Miniotis and colleagues was recently published in the scientific journal PLOS. The article can be found at dx.doi.org/10.1371/journal.pone.0106546
For additional information, please contact:
Peter Egelberg, CEO
Tel: +46 703 19 42 74
Phase Holographic Imaging (PHI) is the leader in the development of proprietary ground-breaking holographic time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of cellular dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.